Thyroid eye disease

Zhen Li; Dean M. Cestari; Elizabeth Fortin

doi:10.1097/icu.0000000000000529

journal article Nov 01, 2018

Thyroid eye disease

Zhen Li

Dean M. Cestari Elizabeth Fortin

Current Opinion in Ophthalmology Vol. 29 No. 6 pp. 528-534 · Ovid Technologies (Wolters Kluwer Health)

View at Publisher Save 10.1097/icu.0000000000000529

Topics

No keywords indexed for this article. Browse by subject →

References

59

[1]

Scott "Thyroid eye disease" Semin Ophthalmol (1999) 10.3109/08820539909056064

[2]

Wall "Pathogenesis of thyroid eye disease—does autoimmunity against the TSH receptor explain all cases?" Endokrynol Pol (2010)

[3]

Wiersinga "Epidemiology and prevention of Graves’ ophthalmopathy" Thyroid (2002) 10.1089/105072502761016476

[4]

Lazarus "Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease" Best Pract Res Clin Endocrinol Metab (2012) 10.1016/j.beem.2011.10.005

[5]

Bartley "The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota" Trans Am Ophthalmol Soc (1994)

[6]

Burch "Graves’ ophthalmopathy: current concepts regarding pathogenesis and management" Endocr Rev (1993)

[7]

Bartley "Clinical Features of Graves’ Ophthalmopathy in an Incidence Cohort" Am J Ophthalmol (1996) 10.1016/s0002-9394(14)70276-4

[8]

Graves' Ophthalmopathy

Rebecca S. Bahn

New England Journal of Medicine 2010 10.1056/nejmra0905750

[9]

Hiromatsu "Graves’ ophthalmopathy: epidemiology and natural history" Intern Med (2014) 10.2169/internalmedicine.53.1518

[10]

Stan "Risk factors for development or deterioration of Graves’ ophthalmopathy" Thyroid (2010) 10.1089/thy.2010.1634

[11]

Khong "Serum selenium status in Graves’ disease with and without orbitopathy: a case-control study" Clin Endocrinol (Oxf (2014) 10.1111/cen.12392

[12]

Stein "Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease" JAMA Ophthalmol (2015) 10.1001/jamaophthalmol.2014.5103

[13]

Sabini "High serum cholesterol is a novel risk factor for graves’ orbitopathy: results of a cross-sectional study" Thyroid (2018) 10.1089/thy.2017.0430

[14]

Borodic "Ipilimumab-induced orbital inflammation resembling Graves disease with subsequent development of systemic hyperthyroidism from CTLA-4 receptor suppression" Ophthalmic Plast Reconstr Surg (2014) 10.1097/iop.0000000000000033

[15]

McElnea "Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab" Orbit (2014) 10.3109/01676830.2014.949792

[16]

Thornton "Cigarette smoking and thyroid eye disease: a systematic review" Eye (Lond (2007) 10.1038/sj.eye.6702603

[17]

Cawood "Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link" J Clin Endocrinol Metab (2007) 10.1210/jc.2006-1824

[18]

Vink "Differential gene expression patterns between smokers and nonsmokers: cause or consequence?" Addict Biol (2017) 10.1111/adb.12322

[19]

Duntas "Selenium and the thyroid: a close-knit connection" J Clin Endocrinol Metab (2010) 10.1210/jc.2010-0191

[20]

Ryder "Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution" Endocr Relat Cancer (2014) 10.1530/erc-13-0499

[21]

Min "Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy" Eur J Endocrinol (2011) 10.1530/eje-10-0833

[22]

Borodic "Drug-induced Graves disease from CTLA-4 receptor suppression" Ophthalmic Plast Reconstr Surg (2011) 10.1097/iop.0b013e3181ef72a1

[23]

Campredon "Severe inflammatory ophthalmopathy in a euthyroid patient during nivolumab treatment" Eur Thyroid J (2018) 10.1159/000485742

[24]

Estcourt "Quality of life in thyroid eye disease: impact of quality of care" Eur J Endocrinol (2011) 10.1530/eje-11-0055

[25]

Prummel "Effect of abnormal thyroid function on the severity of Graves’ ophthalmopathy" Arch Intern Med (1990) 10.1001/archinte.1990.00390170124027

[26]

Li "Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis" J Endocrinol Invest (2016) 10.1007/s40618-016-0484-y

[27]

Marcocci "Selenium and the course of mild graves’ orbitopathy" N Engl J Med (2011) 10.1056/nejmoa1012985

[28]

Bartalena "The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy" Eur Thyroid J (2016) 10.1159/000443828

[29]

Vanderpas "Selenium deficiency mitigates hypothyroxinemia in iodine-deficient subjects" Am J Clin Nutr (1993) 10.1093/ajcn/57.2.271s

[30]

Bartalena "Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active graves’ orbitopathy" J Clin Endocrinol Metab (2012) 10.1210/jc.2012-2389

[31]

Zang "Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy" J Endocrinol Invest (2011) 10.1007/bf03346732

[32]

Pathogenesis of thyroid eye disease: review and update on molecular mechanisms

Jwu Jin Khong, Alan A McNab, Peter R Ebeling et al.

British Journal of Ophthalmology 2015 10.1136/bjophthalmol-2015-307399

[33]

Ostrowski "Rituximab in the treatment of thyroid eye disease: a review" Neuroophthalmology (2015) 10.3109/01658107.2015.1039140

[34]

Silkiss "Rituximab for thyroid eye disease" Ophthalmic Plast Reconstr Surg (2010) 10.1097/iop.0b013e3181c4dfde

[35]

Salvi "Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study" Eur J Endocrinol (2007) 10.1530/eje.1.02325

[36]

Khanna "Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy" Ophthalmology (2010) 10.1016/j.ophtha.2009.05.029

[37]

Salvi "Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe graves’ orbitopathy: a randomized controlled study" J Clin Endocrinol Metab (2015) 10.1210/jc.2014-3014

[38]

Stan "Randomized controlled trial of rituximab in patients with graves’ orbitopathy" J Clin Endocrinol Metab (2015) 10.1210/jc.2014-2572

[39]

Shen "Efficacy and safety of rituximab for the treatment of graves’ orbitopathy: a meta-analysis of randomized controlled trials" Pharmacotherapy (2018) 10.1002/phar.2111

[40]

Wang "Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis" BMC Ophthalmology (2018) 10.1186/s12886-018-0679-4

[41]

Teprotumumab for Thyroid-Associated Ophthalmopathy

Terry J. Smith, George J. Kahaly, Daniel G. Ezra et al.

New England Journal of Medicine 2017 10.1056/nejmoa1614949

[42]

Durrani "Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy" Orbit (2009) 10.1080/01676830590912562

[43]

van Steensel "Whole orbital tissue culture identifies imatinib mesylate and adalimumab as potential therapeutics for Graves’ ophthalmopathy" Br J Ophthalmol (2011) 10.1136/bjo.2010.192302

[44]

Ayabe "Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease" Ophthalmic Plast Reconstr Surg (2014) 10.1097/iop.0000000000000211

[45]

Perez-Moreiras "Treatment of active corticosteroid-resistant graves’ orbitopathy" Ophthalmic Plast Reconstr Surg (2014) 10.1097/iop.0000000000000037

[46]

Rhiu "Effect of tanshinone IIA in an in vitro model of Graves’ orbitopathy" Invest Ophthalmol Vis Sci (2014) 10.1167/iovs.14-14008

[47]

Jafarpour "The radioprotective effects of curcumin and trehalose against genetic damage caused by I-131" Indian J Nucl Med (2018) 10.4103/ijnm.ijnm_158_17

[48]

Prummel "A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild graves’ ophthalmopathy" J Clin Endocrinol Metab (2004) 10.1210/jc.2003-030809

[49]

Gorman "A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy" Ophthalmology (2001) 10.1016/s0161-6420(01)00632-7

[50]

Hao "Treatment of Graves’ ophthalmopathy with an in-house Phosphorus-32 source: Initial clinical observations" Exp Ther Med (2017) 10.3892/etm.2017.4911

Showing 50 of 59 references

Metrics

38

Citations

59

References

Details

Published: Nov 01, 2018
Vol/Issue: 29(6)
Pages: 528-534

Authors

Z

Zhen Li

South China Agricultural University

Cite This Article

Zhen Li, Dean M. Cestari, Elizabeth Fortin (2018). Thyroid eye disease. Current Opinion in Ophthalmology, 29(6), 528-534. https://doi.org/10.1097/icu.0000000000000529

Thyroid eye disease

You May Also Like